Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10481MR)

This product GTTS-WQ10481MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GCRP gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10481MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7515MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ307MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ14949MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ15465MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ11366MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ8761MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ10790MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ10887MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW